# HORTENSIA - Cohort study in chronic kidney disease patients on dialysis starting treatment with Mircera® to correct anemia or maintain stable hemoglobin levels

Head :Roche Medical Data Center

Last update : 08/23/2022   Version : 1   ID : 74133		
General		
Identification		
Detailed name	Cohort study in chronic kidney disease patients on dialysis starting treatment with Mircera® to correct anemia or maintain stable hemoglobin levels	
Sign or acronym	HORTENSIA	
General Aspects		
Medical area	Urology, andrology and nephrology	
Study in connection with Covid- 19	No	
Pathology (details)	Chronic Kidney Disease on dialysis	
Health determinants	latrogenic Medicine	
Keywords	MIRCERA®	
Scientific investigator(s) (Contact)		
Name of the director	Roche Medical Data Center	
Address	4 cours de l'Ile Seguin - 92650 BOULOGNE- BILLANCOURT	
Email	data_sharing_france@roche.com	
Organization	Roche SAS	
Collaborations		
Participation in projects, networks and consortia	No	
Funding		
Funding status	Private	

Governance of the database	
Sponsor(s) or organisation(s) responsible	Roche SAS
Organisation status	Public
Presence of scientific or steering committees	Yes
Additional contact	
Name of the contact	https://www.roche.fr/fr/innovation-recherche- medicale/data-sharing-portail-d-information- partage-des-donnees.html
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Database objective	

Main objective	Primary objective: Describe the management of anemia treatment with Mircera® in routine clinical practice in chronic kidney disease patients on dialysis and to describe their hemoglobin concentration around the 6th month of treatment with Mircera®.
	Secondary objective: In the total population and in each sub-population of patients (hemodialysis and peritoneal dialysis, ESA-naive and non ESA-naive patients):

with Mircera®;

2. Describe the evolution of Hb and hematocrit levels during the observation period;

1. Describe the characteristics of patients treated

3. Describe the biological parameters used to

document renal anemia and any changes in values;

- 4. Describe the parameters influencing treatment response;
- 5. Describe the biological parameters reflecting the efficacy of dialysis;
- 6. Describe the safety profile of Mircera® (serious and/or unexpected adverse drug reactions and targeted adverse drug reactions related to Mircera®);
- 7. Describe treatment compliance with Mircera®;
- 8. Describe the evolution of patients' quality of life, evaluated by the SF-36 questionnaire.

## Inclusion criteria

## Inclusion criteria:

- Adult (aged >= 18 years);
- With CKD and on dialysis for more than 3 months;
- ESA-naive or not:
- For whom the physician decided to initiate treatment with Mircera® for renal anemia at the inclusion visit;
- Who was informed about the study both orally and in writing and who did not object to their personal data being processed.

### Exclusion criteria:

- Patient participating in a clinical study;
- Anemia due to a malignant disease.

# Population type

$\Lambda$		Δ
	١Ч	$\subset$

Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

## Population covered

Sick population

# Pathology

N18 - Chronic kidney disease

#### Gender

Male Woman

## Geography area

National

## Data collection

#### **Dates**

Date of first collection (YYYY or MM/YYYY)

2010

Date of last collection (YYYY or

2011

MM/YYYY)	
Size of the database	
Size of the database (number of individuals)	< 500 individuals
Details of the number of individuals	414
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Biological data
Clinical data (detail)	Medical registration
Details of collected clinical data	Patient provided with information about the study - Demographic and clinical data, concomitant diseases - History of chronic renal failure and dialysis - Previous treatment for CKD-associated anemia: with ESA if any and other potential treatments (iron, folic acid, vitamin B12, blood transfusion over the last 3 months before Mircera® initiation) - Clinical data at the midweek dialysis session: weight after the session, blood pressure at rest and after the session - Most recent available laboratory data: urea and serum creatinine (before and after the dialysis session), urea reduction ratio, Kt/V (hemodialysis), total Kt/V (peritoneal dialysis), Hb, hematocrit, platelet count, reticulocytes, iron status, C-reactive protein, documented deficiency in folic acid or vitamin B12 if any - Treatment of CKD-associated anemia at inclusion: treatment with Mircera® and concomitant treatment if any (iron, folic acid, vitamin B12) - Other treatments: antihypertensives, antiplatelet drugs, anticoagulants, LMWH, lipid-lowering treatments, antidiabetics, immunosuppressors.
Presence of a biobank	No
Health parameters studied	Health care consumption and services
Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	paper
Classifications used	CDISC

Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Dedicated website	https://www.roche.fr/fr/innovation-recherche- medicale/data-sharing-portail-d-information- partage-des-donnees.html
Presence of document that lists variables and coding procedures	Yes
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only